^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HER-2 exon 20 mutation

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Phase 3
Spectrum Pharmaceuticals, Inc
Suspended
Last update posted :
02/15/2024
Initiation :
05/12/2022
Primary completion :
12/25/2027
Completion :
12/25/2028
HER-2
|
HER-2 mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation
|
docetaxel • Pozenveo (poziotinib)
Phase 2
Intergroupe Francophone de Cancerologie Thoracique
Completed
Last update posted :
12/19/2023
Initiation :
05/17/2019
Primary completion :
02/01/2021
Completion :
12/18/2023
HER-2
|
HER-2 mutation • HER-2 exon 20 insertion • HER-2 L755S • HER-2 exon 20 mutation • HER-2 YVMA • HER-2 exon 23 mutation
|
Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab)
Phase 1/2
RemeGen Co., Ltd.
Completed
Last update posted :
12/18/2023
Initiation :
09/26/2018
Primary completion :
12/21/2021
Completion :
05/30/2022
HER-2 • MET
|
EGFR mutation • HER-2 overexpression • HER-2 mutation • MET amplification • EGFR T790M • MET mutation • HER-2 exon 20 mutation
|
Aidixi (disitamab vedotin)
Phase 1/2
RemeGen Co., Ltd.
Not yet recruiting
Last update posted :
11/27/2023
Initiation :
04/01/2024
Primary completion :
12/01/2025
Completion :
12/01/2025
HER-2
|
HER-2 mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation
|
Irene (pyrotinib) • Aidixi (disitamab vedotin)
Phase 1
Jonathan Riess
Not yet recruiting
Last update posted :
10/05/2023
Initiation :
01/01/2024
Primary completion :
01/01/2025
Completion :
11/01/2026
HER-2 • BRAF • ALK • MET • RET
|
EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation
|
Erbitux (cetuximab) • Tagrisso (osimertinib) • Tukysa (tucatinib)
Phase 2
German Cancer Research Center
Recruiting
Last update posted :
07/06/2023
Initiation :
06/29/2023
Primary completion :
03/01/2030
Completion :
12/01/2030
HER-2 • PD-L1 • PIK3CA • TMB • BRCA1 • BRCA2 • PARP1 • TACSTD2
|
HER-2 positive • BRCA2 mutation • BRCA1 mutation • TMB-H • HR positive • MSI-H/dMMR • HER-2 negative • PIK3CA mutation • HER-2 exon 20 insertion • PALB2 mutation • PD-L1 amplification • HR positive + HER-2 negative • HER-2 exon 20 mutation • UGT1A1*28 • UGT1A1*1*1 • HER-2 exon 23 mutation
|
Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Perjeta (pertuzumab) • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
Phase 2
Guangdong Provincial People's Hospital
Recruiting
Last update posted :
04/05/2023
Initiation :
04/04/2023
Primary completion :
12/31/2024
Completion :
12/31/2026
HER-2 • PD-L1 • BRAF • MET • RET
|
BRAF V600E • HER-2 amplification • HER-2 mutation • MET amplification • RET fusion • MET exon 14 mutation • MET mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation
|
carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • pemetrexed
Phase 2
Shanghai Chest Hospital
Recruiting
Last update posted :
01/28/2021
Initiation :
06/30/2020
Primary completion :
10/01/2022
Completion :
04/01/2023
HER-2
|
HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation
|
Irene (pyrotinib) • thalidomide
Phase N/A
University Hospital, Toulouse
Completed
Last update posted :
07/11/2016
Initiation :
03/01/2013
Primary completion :
09/01/2015
Completion :
09/01/2015
HER-2
|
HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation